BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 18848601)

  • 21. Bicyclic substituted hydroxyphenylmethanone type inhibitors of 17 β-hydroxysteroid dehydrogenase Type 1 (17 β-HSD1): the role of the bicyclic moiety.
    Oster A; Klein T; Henn C; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    ChemMedChem; 2011 Mar; 6(3):476-87. PubMed ID: 21337522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estrone and estradiol C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase.
    Poirier D; Chang HJ; Azzi A; Boivin RP; Lin SX
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):236-8. PubMed ID: 16337735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Allan GM; Lawrence HR; Cornet J; Bubert C; Fischer DS; Vicker N; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
    J Med Chem; 2006 Feb; 49(4):1325-45. PubMed ID: 16480268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
    Karkola S; Alho-Richmond S; Wahala K
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
    Oster A; Klein T; Werth R; Kruchten P; Bey E; Negri M; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    Bioorg Med Chem; 2010 May; 18(10):3494-505. PubMed ID: 20413314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of highly potent, nonsteroidal 17β-hydroxysteroid dehydrogenase type 1 inhibitors by virtual high-throughput screening.
    Starčević Š; Turk S; Brus B; Cesar J; Lanišnik Rižner T; Gobec S
    J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):255-61. PubMed ID: 21920439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxidations of 17beta-estradiol and estrone and their interconversions catalyzed by liver, mammary gland and mammary tumor after acute and chronic treatment of rats with indole-3-carbinol or beta-naphthoflavone.
    Ritter CL; Prigge WF; Reichert MA; Malejka-Giganti D
    Can J Physiol Pharmacol; 2001 Jun; 79(6):519-32. PubMed ID: 11430590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Messinger J; Hirvelä L; Husen B; Kangas L; Koskimies P; Pentikäinen O; Saarenketo P; Thole H
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):192-8. PubMed ID: 16413669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 3D QSAR model of 17beta-HSD1 inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core applying molecular dynamics simulations and ligand-protein docking.
    Karkola S; Lilienkampf A; Wähälä K
    ChemMedChem; 2008 Mar; 3(3):461-72. PubMed ID: 18224704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.
    Abdelsamie AS; Salah M; Siebenbürger L; Hamed MM; Börger C; van Koppen CJ; Frotscher M; Hartmann RW
    Eur J Med Chem; 2019 Sep; 178():93-107. PubMed ID: 31176098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities.
    Perspicace E; Cozzoli L; Gargano EM; Hanke N; Carotti A; Hartmann RW; Marchais-Oberwinkler S
    Eur J Med Chem; 2014 Aug; 83():317-37. PubMed ID: 24974351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introduction of an electron withdrawing group on the hydroxyphenylnaphthol scaffold improves the potency of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors.
    Wetzel M; Marchais-Oberwinkler S; Perspicace E; Möller G; Adamski J; Hartmann RW
    J Med Chem; 2011 Nov; 54(21):7547-57. PubMed ID: 21972996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blocking 17β-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach.
    Konings GF; Cornel KM; Xanthoulea S; Delvoux B; Skowron MA; Kooreman L; Koskimies P; Krakstad C; Salvesen HB; van Kuijk K; Schrooders YJ; Vooijs M; Groot AJ; Bongers MY; Kruitwagen RF; ; Romano A
    J Pathol; 2018 Feb; 244(2):203-214. PubMed ID: 29144553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel N-methylsulfonamide and retro-N-methylsulfonamide derivatives as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors with good ADME-related physicochemical parameters.
    Perspicace E; Giorgio A; Carotti A; Marchais-Oberwinkler S; Hartmann RW
    Eur J Med Chem; 2013 Nov; 69():201-15. PubMed ID: 24036043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy.
    Mazumdar M; Fournier D; Zhu DW; Cadot C; Poirier D; Lin SX
    Biochem J; 2009 Dec; 424(3):357-66. PubMed ID: 19929851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Vicker N; Lawrence HR; Allan GM; Bubert C; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
    ChemMedChem; 2006 Apr; 1(4):464-81. PubMed ID: 16892382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical and biological evaluation of novel potent coumarin inhibitor of 17β-HSD type 1.
    Starčević S; Kocbek P; Hribar G; Rižner TL; Gobec S
    Chem Biol Interact; 2011 May; 191(1-3):60-5. PubMed ID: 21232530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural basis for species specific inhibition of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1): computational study and biological validation.
    Klein T; Henn C; Negri M; Frotscher M
    PLoS One; 2011; 6(8):e22990. PubMed ID: 21857977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
    Chetrite GS; Thole HH; Philippe JC; Pasqualini JR
    Anticancer Res; 2004; 24(3a):1433-8. PubMed ID: 15274306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
    Schuster D; Nashev LG; Kirchmair J; Laggner C; Wolber G; Langer T; Odermatt A
    J Med Chem; 2008 Jul; 51(14):4188-99. PubMed ID: 18533708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.